Nabriva raised in a series A financing round, Euro 42m from a group of international life science investors led by Nomura Phase4 Ventures. In addition to Nomura Phase4 Ventures. Nabriva’s portfolio has attracted other blue-chip investors including HBM Partners, The Wellcome Trust, Global Life Science Ventures and the Novartis Venture Fund. Sandoz holds a minority stake in Nabriva.
